We therefore concluded that the supra-additive anti-tumor effects observed with the sunitinib-docetaxel combination might support innovative strategies in the management of advanced prostate cancer, using simultaneous treatments targeting EGFR. This evidence concerns the gene EGFR and prostate cancer.